CN102872073B - Application of Houttuynoid C in preparing drugs for treating ovarian cancer - Google Patents
Application of Houttuynoid C in preparing drugs for treating ovarian cancer Download PDFInfo
- Publication number
- CN102872073B CN102872073B CN201210417094.3A CN201210417094A CN102872073B CN 102872073 B CN102872073 B CN 102872073B CN 201210417094 A CN201210417094 A CN 201210417094A CN 102872073 B CN102872073 B CN 102872073B
- Authority
- CN
- China
- Prior art keywords
- houttuynoid
- ovarian cancer
- application
- drugs
- human ovarian
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses an application of Houttuynoid C in drugs for treating human ovarian cancer, belonging to the technical field of a new application of drugs. Through external MTT (Methyl Thiazolyl Tetrazolium) antineoplastic activity evaluation, the invention discovers that Houttuynoid C also has an obvious inhibition effect on the growth of human ovarian cancer strains HO-8910, HOC1 and OVAC. Thus, Houttuynoid C can be applied to preparing anti-ovarian cancer drugs and has good development and application prospects. The application of Houttuynoid C in drugs for treating human ovarian cancer disclosed by the invention is publicized for the first time; and as the skeleton type is brand new, Houttuynoid C has an unexpectedly strong inhibitory activity to human ovarian cancer cells.
Description
Technical field
The present invention relates to the new purposes of compound H outtuynoid C, relate in particular to the application of Houttuynoid C in preparing ovarian cancer resistance medicament.
Technical background
Cancer is to one of disease of human life's health hazard maximum, has a large amount of people to die from cancer every year.The research and development of cancer therapy drug are the focuses of study of pharmacy always.In antitumor drug, have 74% to be natural product or derivatives thereof, if paclitaxel and derivant thereof are exactly the reasonable antitumor drug of effect clinically at present.Therefore, from natural product, find anticancer compound or lead compound has great importance.
The compound H outtuynoid C the present invention relates to is one and within 2012, delivers (Chen, S. D. et al., 2012. Houttuynoid C_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.) New skeleton compound, this compound has brand-new framework types, current purposes only relates to anti-herpes simplex virus activity (Chen, S. D. et al., 2012. Houttuynoid C_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.), purposes for the Houttuynoid C the present invention relates in preparation treatment ovarian cancer medicine belongs to open first, because framework types belongs to brand-new framework types, and its inhibition for ovarian cancer cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other compounds, possesses outstanding substantive distinguishing features, control for ovarian cancer simultaneously obviously has significant progress.
Summary of the invention
The invention provides the application of compound H outtuynoid C in preparing antitumor drug.
The present invention adopts following technical scheme: the application of Houttuynoid C in preparing ovarian cancer resistance medicament, and the structural formula of Houttuynoid C is as shown in formula I:
Formula I
The present invention finds by the evaluation of external MTT anti-tumor activity, and Houttuynoid C also has significant inhibitory action to the growth of human oophoroma cell line HO-8910, HOC1 and OVAC, suppresses the IC of this 3 strain Growth of Cells
50value is respectively 0.29 ± 0.07 μ M, 0.36 ± 0.07 μ M and 0.19 ± 0.06 μ M.Therefore, Houttuynoid C can, for the preparation of ovarian cancer resistance medicament, have good development prospect.
The purposes of the Houttuynoid C the present invention relates in preparation treatment ovarian cancer medicine belongs to open first, because framework types belongs to brand-new framework types, and its inhibition for ovarian cancer cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other compounds, possess outstanding substantive distinguishing features, the control for ovarian cancer simultaneously obviously has significant progress.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subject to any restriction of specific embodiment, but be limited by claim.
The specific embodiment
The preparation method of compound H outtuynoid C involved in the present invention is referring to document (Chen, S. D. et al., 2012. Houttuynoid C_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subject to any restriction of specific embodiment, but be limited by claim.
Embodiment 1: the preparation of compound H outtuynoid C tablet involved in the present invention:
Get 20 and digest compound Houttuynoid C, add 180 grams of conventional adjuvants preparing tablet, mix, conventional tablet machine is made 1000.
Embodiment 2: the preparation of compound H outtuynoid C capsule involved in the present invention:
Get 20 and digest compound Houttuynoid C, add the conventional adjuvant of preparing capsule as 180 grams of starch, mix, encapsulatedly make 1000.
Below by pharmacodynamic experiment, further illustrate its pharmaceutically active.
Experimental example: adopt the growth inhibited effect of mtt assay assessing compound Houttuynoid C to human oophoroma cell line
1. method: the cell in growth logarithmic (log) phase: human oophoroma cell line HO-8910, HOC1 and OVAC(buy from Chinese Academy of Sciences's cell bank) with 1.5 * 10
4concentration kind is in 96 orifice plates.After cell culture 24 h are adherent, suck original culture medium.Test is divided into blank group, drug treating group.Blank group is changed 1640 culture medium containing 10% hyclone; It is 100 μ M that drug treating group is changed containing concentration, 50 μ M, 10 μ M, 1 μ M, 0.1 μ M, the culture medium of the Houttuynoid C of 0.01 μ M and 0.001 μ M.Cultivate after 48 h, add the MTT of concentration 5mg/mL, continue to be put in CO
2incubator is cultivated 4 h, then along culture fluid top, suck 100 μ L supernatants, add 100 μ L DMSO, 10 min are placed in dark place, utilize microplate reader (Sunrise company product) to measure light absorption value (wavelength 570nm), and calculating cell survival situation according to light absorption value, 6 repeating holes are established in each processing.Cell survival rate (%)=Δ OD
drug treating/ Δ OD
blank* 100.
2. result: Houttuynoid C has significant inhibitory action to the growth of human oophoroma cell line HO-8910, HOC1 and OVAC.This compound suppresses the IC of human oophoroma cell line HO-8910, HOC1 and OVAC growth
50value is respectively: 0.29 ± 0.07 μ M, 0.36 ± 0.07 μ M and 0.19 ± 0.06 μ M.
By above-described embodiment, shown, Houttuynoid C of the present invention has good inhibitory action to the growth of human oophoroma cell line HO-8910, HOC1 and OVAC.Prove thus, Houttuynoid C of the present invention has ovarian cancer resistance activity, can be for the preparation of ovarian cancer resistance medicament.
Claims (1)
- The application of 1.Houttuynoid C in preparation treatment ovarian cancer medicine, described compound H outtuynoid C-structure as formula Ishown in:
formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210417094.3A CN102872073B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid C in preparing drugs for treating ovarian cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210417094.3A CN102872073B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid C in preparing drugs for treating ovarian cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102872073A CN102872073A (en) | 2013-01-16 |
| CN102872073B true CN102872073B (en) | 2014-04-16 |
Family
ID=47473744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210417094.3A Expired - Fee Related CN102872073B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid C in preparing drugs for treating ovarian cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102872073B (en) |
-
2012
- 2012-10-27 CN CN201210417094.3A patent/CN102872073B/en not_active Expired - Fee Related
Non-Patent Citations (2)
| Title |
|---|
| Houttuynoids A-E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata;Shao-Dan Chen等;《Organic Letters》;20120313;第14卷(第7期);1772-1775 * |
| Shao-DanChen等.HouttuynoidsA-E Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata.《Organic Letters》.2012 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102872073A (en) | 2013-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102861099B (en) | Application of Houttuynoid D in preparing medicine for treating endometrial cancer | |
| CN102872089B (en) | Application of Houttuynoid E in preparing medicines for treating skin cancer | |
| CN102872073B (en) | Application of Houttuynoid C in preparing drugs for treating ovarian cancer | |
| CN102872142B (en) | Application of Houttuynoid D in drug for treating ovarian cancer | |
| CN102872080B (en) | Application of Houttuynoid A in drugs for treating cervical cancer | |
| CN102872074B (en) | Application of Houttuynoid C in drugs for treating kidney cancer | |
| CN102872076B (en) | Application of Houttuynoid A in drugs for treating tongue cancer | |
| CN102872077B (en) | Application of Houttuynoid B in drugs for treating endometrial cancer | |
| CN102861077B (en) | Application of Houttuynoid D in medicine for treating cervical cancer | |
| CN102861096B (en) | Application of Houttuynoid E in preparing medicine for treating cervical cancer | |
| CN102872081B (en) | Application of Houttuynoid C in drugs for treating gastric cancer | |
| CN102861080B (en) | Application of Houttuynoid C in medicine for treating nasopharynx cancer | |
| CN102872072B (en) | Application of Houttuynoid B to preparing drugs for treating kidney cancer | |
| CN102872070B (en) | Application of Houttuynoid C to preparing drugs for treating prostate cancer | |
| CN102861062B (en) | Application of Houttuynoid C in endometrial cancer treatment medicine | |
| CN102872075A (en) | Application of Houttuynoid E in drugs for treating breast cancer | |
| CN102872085B (en) | Application of Houttuynoid A in medicines for treating breast cancer | |
| CN102872125B (en) | Application of Houttuynoid C in medicament for treating cervical cancer | |
| CN102872137B (en) | Application of Houttuynoid B in drug for treating cervical cancer | |
| CN102872010B (en) | Application of Aphanamixoid A in drugs for treating ovarian cancer | |
| CN102872138B (en) | Application of Houttuynoid C in drug for treating colorectal cancer | |
| CN102861079B (en) | Application of Houttuynoid B in medicine for treating skin cancer | |
| CN102872139B (en) | Application of Houttuynoid C in drug for treating tongue cancer | |
| CN102861052B (en) | Application of Houttuynoid A in medicine for treating ileocecum cancer | |
| CN102861074B (en) | Application of Houttuynoid B in medicine for treating bladder cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140416 Termination date: 20151027 |
|
| EXPY | Termination of patent right or utility model |